NASDAQ: ACRV - Acrivon Therapeutics, Inc.

Доходность за полгода: -76.26%
Дивидендная доходность: 0.00%
Сектор: Healthcare

График акции Acrivon Therapeutics, Inc.

Расширенный график Простой график
Financial Markets by TradingView

О компании Acrivon Therapeutics, Inc.

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.

подробнее
Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in a potentially registrational Phase 2 trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response and cell cycle regulation pathways, such as WEE1, a protein kinase and PKMYT1, a protein serine/threonine kinase. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
Добавить в список сравнения
Добавить в список отслеживания
Добавить в портфель
Добавить уведомление о цене

IPO date 2022-11-15
ISIN US0048901096
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.acrivon.com
Цена ао 2.61
Изменение цены за день: +22.67% (1.5)
Изменение цены за неделю: +35.29% (1.36)
Изменение цены за месяц: -66.18% (5.44)
Изменение цены за 3 месяца: -66.91% (5.56)
Изменение цены за полгода: -76.26% (7.75)
Изменение цены за год: -80.57% (9.47)
Изменение цены с начала года: -72.5% (6.69)
Все параметры

Недооценка

Название Значение Оценка
P/S 0 0
P/BV 0.9109 9
P/E 0 0
EV/EBITDA -1.18 0
Итого: 3.63

Эффективность

Название Значение Оценка
ROA, % -43.68 0
ROE, % -49.83 0
Итого: 0

Дивиденды

Название Значение Оценка
Div yield, % 0 0
DSI 0 0
Итого: 0

Долг

Название Значение Оценка
Debt/EBITDA -0.0696 10
Итого: 10

Импульс роста

Название Значение Оценка
Доходность Revenue, % 0 0
Доходность Ebitda, % 1770.38 10
Доходность EPS, % 564.2 10
Итого: 8
Подробнее

Институционалы Объем Доля, %
RA Capital Management, L.P. 4810508 21.25
Perceptive Advisors LLC 3007858 13.29
Sands Capital Ventures, LLC 1652605 7.3
Citadel Advisors Llc 1649659 7.29
Wellington Management Group, LLP 888130 3.92
Marshall Wace LLP 597469 2.64
Blackrock Inc. 565832 2.5
Vanguard Group Inc 475977 2.1
NEA Management Company, LLC 430252 1.9
Federated Hermes, Inc. 226375 1



Руководитель Должность Оплата Год рождения
Dr. Peter Blume-Jensen M.D., Ph.D. Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer 977.7k 1963 (62 года)
Ms. Kristina Masson M.B.A., Ph.D. Co-Founder, Executive VP of Business Operations, Site Head, Treasurer, Secretary & Director 739.78k 1981 (44 года)
Mr. Rasmus Holm-Jorgensen Chief Financial Officer 1M 1972 (53 года)
Dr. Eric J. Devroe Ph.D. Chief Operating Officer 614.78k 1979 (46 лет)
Ms. Katharine Peterson CPA Vice President of Finance & Accounting N/A
Dr. Adam D. Levy M.B.A., Ph.D. Senior VP and Head of Investor Relations & Corporate Affairs N/A
Mr. Bruce Close Vice President of Quality & Compliance N/A
Ms. Mary-Alice Miller J.D. Chief Legal Officer 587.11k 1974 (51 год)
Ms. Parvin Miah VP & Head of Human Resources N/A
Dr. Erick Gamelin M.D., Ph.D. Chief Development Officer 480.72k 1958 (67 лет)

Адрес: United States, Watertown. MA, 480 Arsenal Way - открыть в Google картах, открыть Яндекс картах
Сайт: https://www.acrivon.com